Total Payments
$45,241
2024 Payments
$675.48
Companies
22
Transactions
349
Medicare Patients
90
Medicare Billing
$9,166
Payment Breakdown by Category
Other$25,638 (56.7%)
Food & Beverage$7,211 (15.9%)
Consulting$7,210 (15.9%)
Travel$4,188 (9.3%)
Research$979.47 (2.2%)
Education$14.91 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,638 | 15 | 56.7% |
| Food and Beverage | $7,211 | 304 | 15.9% |
| Consulting Fee | $7,210 | 2 | 15.9% |
| Travel and Lodging | $4,188 | 10 | 9.3% |
| Unspecified | $979.47 | 14 | 2.2% |
| Education | $14.91 | 4 | 0.0% |
Payments by Type
General
$44,261
335 transactions
Research
$979.47
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $16,831 | 54 | $0 (2023) |
| Biogen, Inc. | $13,792 | 3 | $0 (2023) |
| Indivior Inc. | $5,045 | 19 | $0 (2024) |
| Allergan, Inc. | $2,055 | 23 | $0 (2020) |
| F. Hoffmann-La Roche AG | $1,787 | 3 | $0 (2017) |
| Teva Pharmaceuticals USA, Inc. | $1,465 | 41 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $847.63 | 52 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $673.89 | 58 | $0 (2022) |
| Vanda Pharmaceuticals Inc. | $469.15 | 26 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $410.62 | 5 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $675.48 | 32 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($164.39) |
| 2023 | $6,257 | 48 | Biogen, Inc. ($4,675) |
| 2022 | $18,807 | 59 | Alkermes, Inc. ($9,333) |
| 2021 | $7,258 | 38 | Alkermes, Inc. ($6,769) |
| 2020 | $539.84 | 32 | Sunovion Pharmaceuticals Inc. ($164.50) |
| 2019 | $1,034 | 43 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($219.46) |
| 2018 | $7,792 | 64 | Indivior Inc. ($4,893) |
| 2017 | $2,876 | 33 | F. Hoffmann-La Roche AG ($1,787) |
All Payment Transactions
349 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $17.84 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/09/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: PSYCHIATRY | ||||||
| 11/21/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: PSYCHIATRY | ||||||
| 11/18/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $0.68 | General |
| Category: PSYCHIATRY | ||||||
| 11/06/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: Central Nervous System | ||||||
| 11/01/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MYCITE (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: PSYCHIATRY | ||||||
| 10/25/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: PSYCHIATRY | ||||||
| 09/14/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $23.91 | General |
| Category: PSYCHIATRY | ||||||
| 09/03/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: Neuroscience | ||||||
| 08/14/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: Central Nervous System | ||||||
| 07/30/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $24.35 | General |
| Category: Neuropsychiatry | ||||||
| 07/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: PSYCHIATRY | ||||||
| 07/04/2024 | Indivior Inc. | — | Food and Beverage | In-kind items and services | $15.14 | General |
| 06/26/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: Neuroscience | ||||||
| 06/21/2024 | Otsuka America Pharmaceutical, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: NEUROLOGY | ||||||
| 06/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $12.84 | General |
| Category: PSYCHIATRY | ||||||
| 05/14/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: Neurology | ||||||
| 05/09/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $83.33 | General |
| Category: Psychiatry/Psychology | ||||||
| 05/06/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: PSYCHIATRY | ||||||
| 04/25/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: PSYCHIATRY | ||||||
| 04/23/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MYCITE (Drug) | Food and Beverage | In-kind items and services | $19.86 | General |
| Category: PSYCHIATRY | ||||||
| 04/03/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: PSYCHIATRY | ||||||
| 03/27/2024 | Indivior Inc. | PERSERIS (Drug) | Food and Beverage | In-kind items and services | $13.99 | General |
| Category: BH | ||||||
| 03/19/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: Central Nervous System | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia | Teva Pharmaceuticals USA, Inc. | $760.01 | 11 |
| A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $219.46 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 14 | 17 | $1,700 | $643.97 |
| 2021 | 1 | 36 | 61 | $6,100 | $3,351 |
| 2020 | 1 | 40 | 90 | $9,000 | $5,171 |
Total Patients
90
Total Services
168
Medicare Billing
$9,166
Procedure Codes
3
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 17 | $1,700 | $643.97 | 37.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 36 | 61 | $6,100 | $3,351 | 54.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 40 | 90 | $9,000 | $5,171 | 57.5% |
About Dr. David Brown, M.D
Dr. David Brown, M.D is a Psychiatry healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/28/2007. The National Provider Identifier (NPI) number assigned to this provider is 1518086743.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Brown, M.D has received a total of $45,241 in payments from pharmaceutical and medical device companies, with $675.48 received in 2024. These payments were reported across 349 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($25,638).
As a Medicare-enrolled provider, Brown has provided services to 90 Medicare beneficiaries, totaling 168 services with total Medicare billing of $9,166. Data is available for 3 years (2020–2022), covering 3 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Austin, TX
- Active Since 03/28/2007
- Last Updated 07/09/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1518086743
Products in Payments
- LYBALVI (Drug) $15,807
- PERSERIS (Drug) $3,287
- Non-Covered Product (Drug) $1,787
- VRAYLAR (Drug) $1,522
- LATUDA (Drug) $673.89
- AUSTEDO (Drug) $588.01
- REXULTI (Drug) $561.30
- ARISTADA (Drug) $464.77
- CAPLYTA (Drug) $346.75
- ABILIFY MAINTENA (Drug) $289.83
- HETLIOZ (Drug) $242.89
- Fanapt (Drug) $209.36
- INVEGA SUSTENNA (Drug) $145.31
- ABILIFY MYCITE (Drug) $135.41
- NUEDEXTA (Drug) $129.65
- VIVITROL (Drug) $103.31
- COBENFY (Drug) $101.17
- Austedo XR (Drug) $86.77
- INGREZZA (Drug) $78.51
- BELSOMRA (Drug) $66.87
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Austin
Dr. Donald Garcia, Md, MD
Psychiatry — Payments: $4.0M
Psychiatry $4.0M
Dr. Arvinder Pal Walia, M.d, M.D
Psychiatry — Payments: $2.7M
Psychiatry $2.7M
Charles Nemeroff, Md Phd, MD PHD
Psychiatry — Payments: $400,808
Psychiatry $400,808
Dr. Divyansu Patel, M.d, M.D
Psychiatry — Payments: $319,461
Psychiatry $319,461
Frank Floca, Md, MD
Psychiatry — Payments: $99,177
Psychiatry $99,177
Dr. Charles Sweet, M.d., M.p.h, M.D., M.P.H
Psychiatry — Payments: $88,371
Psychiatry $88,371